• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺特异性膜抗原(PSMA)与一种前列腺特异性膜抗原样基因的比较分析

Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.

作者信息

O'Keefe Denise S, Bacich Dean J, Heston Warren D W

机构信息

The Department of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

出版信息

Prostate. 2004 Feb 1;58(2):200-10. doi: 10.1002/pros.10319.

DOI:10.1002/pros.10319
PMID:14716746
Abstract

BACKGROUND

Currently prostate-specific membrane antigen (PSMA) is showing promise both as an imaging and therapeutic target for occult prostate cancer metastases. First generation antibodies against PSMA are used for the FDA approved Prostascint trade mark monoclonal antibody scan and second generation antibodies are being developed for therapeutic targeting as well as imaging 1. However, there have been reports describing PSMA expression in non-prostatic tissues including kidney, liver, and brain. As we had previously showed the existence of a human PSMA homolog, we set out to determine if this non-prostatic expression was due to expression of the PSMA or another gene.

MATERIALS AND METHODS

The PSMA homolog (PSMA-like) cDNA was cloned by screening a liver cDNA library. mRNA expression of the PSMA and PSMA-like genes was determined via Northern blot analysis using two different probes and protein expression confirmed in some tissues via Western blot analysis. Transcriptional regulation of the two genes was examined using reporter constructs driving luciferase expression.

RESULTS

The PSMA-like gene possesses 98% identity to the PSMA gene at the nucleotide level and is expressed in kidney and liver under the control of a different promoter to the PSMA gene. The PSMA gene is expressed in several human tissues and is most abundant in the nervous system and the prostate.

CONCLUSION

The non-prostatic expression of PSMA should be taken into consideration when designing clinical strategies targeting PSMA.

摘要

背景

目前,前列腺特异性膜抗原(PSMA)作为隐匿性前列腺癌转移灶的成像和治疗靶点显示出前景。第一代抗PSMA抗体用于美国食品药品监督管理局(FDA)批准的Prostascint商标单克隆抗体扫描,第二代抗体正在开发用于治疗靶向以及成像。然而,有报道描述PSMA在包括肾脏、肝脏和大脑在内的非前列腺组织中表达。由于我们之前已证明人PSMA同源物的存在,我们着手确定这种非前列腺组织中的表达是由于PSMA还是另一个基因的表达所致。

材料与方法

通过筛选肝脏cDNA文库克隆PSMA同源物(PSMA样)cDNA。使用两种不同探针通过Northern印迹分析确定PSMA和PSMA样基因的mRNA表达,并通过Western印迹分析在某些组织中确认蛋白质表达。使用驱动荧光素酶表达的报告基因构建体检查这两个基因的转录调控。

结果

PSMA样基因在核苷酸水平与PSMA基因具有98%的同一性,并且在与PSMA基因不同的启动子控制下在肾脏和肝脏中表达。PSMA基因在几种人体组织中表达,在神经系统和前列腺中最为丰富。

结论

在设计针对PSMA的临床策略时,应考虑PSMA在非前列腺组织中的表达。

相似文献

1
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.前列腺特异性膜抗原(PSMA)与一种前列腺特异性膜抗原样基因的比较分析
Prostate. 2004 Feb 1;58(2):200-10. doi: 10.1002/pros.10319.
2
High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.前列腺癌中PSM-E的高表达与肿瘤分级相关:一种新的前列腺特异性膜抗原可变剪接变体
Prostate. 2007 Dec 1;67(16):1791-800. doi: 10.1002/pros.20664.
3
[The construction of recombinant plasmid with prostate-specific membrane antigen promoter controlling reporter gene expression].[构建具有前列腺特异性膜抗原启动子控制报告基因表达的重组质粒]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Mar;36(2):169-71.
4
Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.构建具有前列腺特异性膜抗原(PSMA)启动子/增强子高转录活性的前列腺特异性表达重组质粒。
J Androl. 2005 Mar-Apr;26(2):215-21. doi: 10.1002/j.1939-4640.2005.tb01088.x.
5
Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.利用前列腺特异性膜抗原启动子/增强子在前列腺癌细胞中进行组织选择性RNA干扰。
Urol Oncol. 2009 Sep-Oct;27(5):539-47. doi: 10.1016/j.urolonc.2008.05.003. Epub 2008 Jul 17.
6
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.前列腺癌患者中前列腺特异性膜抗原及PSMA三种可变剪接变体的表达
Int J Cancer. 2003 Nov 1;107(2):323-9. doi: 10.1002/ijc.11402.
7
[Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer].[前列腺特异性膜抗原在前列腺癌诊断和治疗中的最新应用]
Zhonghua Nan Ke Xue. 2008 Jan;14(1):79-82.
8
PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.PGC 和 PSMA 在前列腺癌诊断中的应用:活检样本的组织分析。
Int Braz J Urol. 2013 Sep-Oct;39(5):649-56. doi: 10.1590/S1677-5538.IBJU.2013.05.06.
9
Clinical significance of PSMA, TERT and PDEF in malignant tumors of the prostate.PSMA、TERT 和 PDEF 在前列腺恶性肿瘤中的临床意义。
Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3347-3352.
10
Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.在前列腺特异性膜抗原启动子/增强子的控制下,通过自杀基因/前药系统(尿嘧啶磷酸核糖基转移酶/5-氟尿嘧啶)在体外对前列腺癌细胞进行特异性靶向。
Prostate Cancer Prostatic Dis. 2009;12(2):166-71. doi: 10.1038/pcan.2008.39. Epub 2008 Jul 15.

引用本文的文献

1
Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics.通过白蛋白结合竞争剂设计一种具有白蛋白结合部分并进行药代动力学调控的放射性杂交PSMA配体用于放射治疗诊断。
Molecules. 2025 Jun 29;30(13):2804. doi: 10.3390/molecules30132804.
2
JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.在前列腺特异性膜抗原(PSMA)靶向成像过程中,JHU - 2545能优先保护唾液腺和肾脏。
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1631-1641. doi: 10.1007/s00259-024-07044-7. Epub 2025 Jan 2.
3
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer - a narrative review.
精准打击:前列腺癌中靶向前列腺特异性膜抗原的放射性核素治疗——一篇综述
Front Oncol. 2023 Nov 16;13:1239118. doi: 10.3389/fonc.2023.1239118. eCollection 2023.
4
AptaTrans: a deep neural network for predicting aptamer-protein interaction using pretrained encoders.AptaTrans:一种使用预训练编码器预测适配体-蛋白质相互作用的深度神经网络。
BMC Bioinformatics. 2023 Nov 27;24(1):447. doi: 10.1186/s12859-023-05577-6.
5
The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy.前列腺特异性膜抗原(PSMA)作为前列腺癌治疗特异性靶点的“来龙去脉”。
Adv Exp Med Biol. 2023;1408:291-308. doi: 10.1007/978-3-031-26163-3_16.
6
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of Lu-PSMA-617 in prostate cancer patients.利用影像数据评估前列腺癌患者 Lu-PSMA-617 药代动力学变异性的群体药代动力学剂量学模型。
CPT Pharmacometrics Syst Pharmacol. 2023 Aug;12(8):1060-1071. doi: 10.1002/psp4.12914. Epub 2023 Feb 9.
7
Imaging of Tumor-Associated Vascular Prostate-Specific Membrane Antigen in Woodchuck Model of Hepatocellular Carcinoma.土拨鼠肝细胞癌模型中肿瘤相关血管前列腺特异性膜抗原的成像
Gastro Hep Adv. 2022;1(4):631-639. doi: 10.1016/j.gastha.2022.04.014. Epub 2022 Apr 28.
8
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.在转移性去势抵抗性前列腺癌患者中,每四周接受三个周期 PSMA-617 治疗后肾脏和唾液腺功能。
Curr Oncol. 2021 Sep 23;28(5):3692-3704. doi: 10.3390/curroncol28050315.
9
Kidney Protection with the Radical Scavenger α-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy.在肽受体放射性核素治疗和放射性配体治疗期间,用自由基清除剂α-微球蛋白(A1M)保护肾脏。
Antioxidants (Basel). 2021 Aug 10;10(8):1271. doi: 10.3390/antiox10081271.
10
Epigenetic age prediction in semen - marker selection and model development.精液中的表观遗传年龄预测——标志物选择与模型开发。
Aging (Albany NY). 2021 Aug 10;13(15):19145-19164. doi: 10.18632/aging.203399.